Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced a webcast and conference call to provide top-line results from a Phase 2 clinical trial of ADX‑629 in patients with atopic dermatitis.
12/18/2023 - 04:01 PM
LEXINGTON, Mass. --(BUSINESS WIRE)--
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial of ADX‑629 in patients with atopic dermatitis.
The dial-in numbers are (888) 415-4305 for domestic callers and (646) 960-0336 for international callers. The access code is 5858366. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra's website at ir.aldeyra.com .
After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX‑629, ADX‑246, ADX‑248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of proliferative vitreoretinopathy and retinitis pigmentosa.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231218552145/en/
Investor & Media:
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
When will Aldeyra Therapeutics, Inc. host the webcast and conference call?
Aldeyra Therapeutics, Inc. will host the webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET).
What is the ticker symbol for Aldeyra Therapeutics, Inc.?
The ticker symbol for Aldeyra Therapeutics, Inc. is ALDX.
What is the Phase 2 clinical trial of ADX‑629 focused on?
The Phase 2 clinical trial of ADX‑629 is focused on patients with atopic dermatitis.
How can I access the live audio webcast of the conference call?
The live audio webcast of the conference call will be accessible from the “Investors & Media” section of Aldeyra's website at ir.aldeyra.com.
How long will the event be archived on Aldeyra’s website?
The event will remain archived on Aldeyra’s website for 90 days after the live webcast.
ALDX Rankings
#5198 Ranked by Stock Gains
ALDX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About ALDX
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
